Department of Orthopedics, Dhulikhel Hospital- Kathmandu University Hospital.
Research and Development Division, Dhulikhel Hospital, Dhulikhel, Nepal.
J Nepal Health Res Counc. 2023 Jul 20;20(4):942-946. doi: 10.33314/jnhrc.v20i4.4323.
Designated as a "priority disease" by World Health Organization, Osteoarthritis is the most common chronic rheumatic disease. Providing a proper treatment for Osteoarthritis is still a major public health challenge. Diacerein has been proposed as a slow acting, symptom modifying or even disease modifying drug used in Osteoarthritis having a risk-benefit ratio far better than conventionally used drugs. However, the evidence of efficacy and safety of use of Diacerein in Osteoarthritis is yet to be explored. Hence, this study attempted to investigate the efficacy and safety of Diacerein in the management of knee osteoarthritis.
This is an analytical cohort study comparing Diacerein with Non-steroidal anti-inflammatory drugs for two months in the management of knee OA. Efficacy was assessed by scores of Lysholm Knee Scoring Scale, Knee injury and Osteoarthritis Outcome Score - Physical Function Short form and Western Ontario and McMaster Universities Osteoarthritis Index.
After two months of treatment, the post- treatment scores were significantly superior to the baseline scores in both the treatment groups (p<0.001). There were no significant differences among the post-treatment scores in two different treatment groups (p>0.05). Discoloration of urine and gastritis were the frequently reported adverse effects in Diacerein treatment group and Non-steroidal anti-inflammatory drugs treatment group respectively.
Our findings have shown Diacerein is as effective as Non-steroidal anti-inflammatory drugs in treating knee OA patients. Diacerein was generally well tolerated, with a good safety profile. These findings indicate the need for further studies with experimental study design in larger scale.
骨关节炎被世界卫生组织列为“重点疾病”，是最常见的慢性风湿性疾病。为骨关节炎提供适当的治疗仍然是一个主要的公共卫生挑战。双醋瑞因已被提议作为一种具有风险效益比远优于传统药物的慢作用、症状改善甚至疾病改善药物，用于骨关节炎。然而，双醋瑞因在骨关节炎中的疗效和安全性证据仍有待探索。因此，本研究试图探讨双醋瑞因在膝关节骨关节炎治疗中的疗效和安全性。
这是一项分析性队列研究，比较了双醋瑞因与非甾体抗炎药在膝关节骨关节炎治疗中的两个月疗效。采用 Lysholm 膝关节评分量表、膝关节损伤和骨关节炎结局评分-物理功能简短表和西安大略和麦克马斯特大学骨关节炎指数评估疗效。
治疗两个月后，两组治疗后的评分均明显优于基线评分（p<0.001）。两组治疗后评分之间无显著差异（p>0.05）。双醋瑞因治疗组和非甾体抗炎药治疗组分别报告了尿液变色和胃炎等不良反应。
我们的研究结果表明，双醋瑞因与非甾体抗炎药治疗膝骨关节炎患者同样有效。双醋瑞因一般耐受性良好，安全性良好。这些发现表明需要进一步进行更大规模的实验性研究设计研究。
